Global Blood Therapeutics Price

November 27, 2020 Post a Comment

South San Francisco Calif. Global Blood Therapeutics GBT stock price prediction is 95058107 USD.

Global Blood Therapeutics Gbt Market Capitalization

In comparing Global Blood Therapeutics Inc.

Global blood therapeutics price. GBTs stock with other industry players reveals that stocks latest price change of -593 and that of -4979 over the past 12 months is in competing position with that of Bristol-Myers Squibb Company BMY which saw its stock price fell by -062 in the recent trading and went through an increase of 541 in past 12-month trading. The Price to Earnings PE ratio a key valuation measure is calculated by dividing the stocks most recent closing price by the sum of the diluted. 102 rows Discover historical prices for GBT stock on Yahoo Finance.

View daily weekly or monthly. The Global Blood Therapeutics stock forecast is 95058107 USD for 2022 May 08 Sunday. News Global Blood Therapeutics IncGBT.

The firm has a market capitalization of 235 billion a price-to-earnings ratio of. The company reported boring third-quarter 2018 operating results but followed up. Latest Share Price and Events.

Get the latest Global Blood Therapeutics stock price and detailed information including GBT news historical charts and realtime prices. 31 2020 at 804 am. Global Blood Therapeutics Inc.

Global Blood Therapeutics has a one year low of 3601 and a one year high of 7954. GBT is not significantly more volatile than the rest of US stocks over the past 3 months typically moving - 7 a week. Global Blood Therapeutics NASDAQGBT had its target price reduced by Canaccord Genuity from 4500 to 4000 in a report issued on Wednesday Benzinga reports.

The companys fifty day moving average price is 4100 and its 200-day moving average price is 4480. ET by Tomi Kilgore Global Blood Therapeutics downgraded to hold from buy at SunTrust RH. GBTNASDAQ GS Stock Quote - Global Blood Therapeutics Inc - Bloomberg Markets.

Global Blood Therapeutics has a beta of 139 meaning that its stock price. Maxx Chatsko Dec 11 2018. Global Blood Therapeutics Inc a biopharmaceutical company engages in the discovery development and delivery of treatments for underserved patient communities.

Global Blood Therapeutics stock was trading at 5485 on March 11th 2020 when Coronavirus COVID-19 reached pandemic status according to the World Health Organization WHO. Global Blood Therapeutics Inc GBT stock is down 657 over the past week and gets a Neutral rating from InvestorsObservers Sentiment Indicator. Since then GBT stock has decreased by 355 and is now trading at 3538.

Global Blood Therapeutics stock price target cut to 75 from 110 at SunTrust RH Jan. External links are being provided as a convenience and for informational purposes only. 19 hours agoGiven Global Blood Therapeutics higher probable upside analysts clearly believe Global Blood Therapeutics is more favorable than Xenetic Biosciences.

Several other equities research analysts also recently commented on the company. Heres Why Global Blood Therapeutics Fell 101 in November Then Jumped 37 Since. You are now leaving the Global Blood Therapeutics website You are currently leaving our site.

And 431900 USD for 2026 May 08 Friday with technical analysis. They currently have a hold rating on the stock. How has Global Blood Therapeuticss share price performed over time and what events caused price changes.

On 31 December 2020 the US2. They do not constitute an endorsement or an approval by Global Blood Therapeutics. GBT Quick Quote GBT - Free Report incurred a loss of 121 per share in first-quarter 2021 wider than the Zacks Consensus Estimate of a.

View which stocks have been most impacted by COVID-19. Global Blood Therapeutics Inc. Zacks Investment Research upgraded Global Blood Therapeutics from a sell rating.

Gbt Institutional Ownership Global Blood Therapeutics Inc